With another GH/IGF-axis medicine
Safety flag
Duplicate GH/IGF-axis stimulation may amplify IGF-1 elevation, edema, joint symptoms, and glucose intolerance.
Interaction evidence source All research profiles
GH secretagogue
Sermorelin
Prepared by the ezGLP team. Sources last checked .
Routes represented in the knowledgebase: Subcutaneous (SubQ).
Educational overview
Sermorelin is listed in the ezGLP knowledgebase under GH secretagogue. Evidence and regulatory status can vary by formulation, route, and jurisdiction.
- Category
- GH secretagogue
- Routes represented
- Subcutaneous (SubQ)
- Approximate library half-life
- 0.2 hours; formulation-dependent and not dosing guidance
- Storage context
- Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.
Published literature
Interaction evidence
These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.
Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.
For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.